Clinical trials: Antiphospholipid Syndrome (APS)
Antiphospholipid Syndrome
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
The purpose of this study is to gather information about causes and treatment of Antiphospholipid Syndrome.
- Trial name
- APS (NCT00616317)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, Davis
Antiphospholipid Syndrome in Pregnancy, Anticoagulants
HYDROxychloroquine in Syndrome Primary AntiPhospholipid
Antiphospholipid syndrome (APS) is defined by thrombosis or obstetric complication (≥ 3 spontaneous miscarriages or fetal death or prematurity <34 weeks gestation-related amenorrhea (SA)) associated with antiphospholipid…
- Trial name
- HYDROSAPL (NCT04275778)
- Testing
- Plaquenil 200Mg Tablet
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anti Phospholipid Syndrome
Telitacicept in Primary APS Patients
This is a single-arm pilot study in Peking Union Medical College Hospital. Telitacicept will be added on traditional antithrombotic and immunosuppressive treatment in primary antiphospholipid syndrome (APS) patients with three…
- Trial name
- NCT05078710
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Antiphospholipid Syndrome, Venous Thromboembolism
Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome
Retrospective monocentric registry to evaluate the efficacy and safety of different anticoagulants in patients with thromboembolic antiphospholipid syndrome
- Conditions
- Antiphospholipid Syndrome, Venous Thromboembolism, Arterial Thromboembolism, Major Bleed
- Trial name
- NCT05195372
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Antiphospholipid Syndrome (APS)
Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome
This study evaluates the benefits of hydroxychloroquine on arterial function in antiphospholipid syndrome. Briefly, the patients will be randomized in two groups, one will receive hydroxychloroquine and standard treatment, the…
- Trial name
- APLAQUINE (NCT02595346)
- Testing
- Hydroxychloroquine
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Rouen
Antiphospholipid Syndrome (APS), Venous Thrombosis (Disorder)
Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients
This is an observational study designed to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) for the secondary prevention of thrombosis in patients with…
- Conditions
- Antiphospholipid Syndrome (APS), Venous Thrombosis (Disorder), Thrombophilia
- Trial name
- DOACS-APS (NCT07372170)
- Where
- 2 sites in Spain
- Volunteers
- 600 people
- Sponsor
- Infanta Leonor University Hospital
Recurrent Miscarriage, Antiphospholipid Syndrome
Use of Warfarin After the First Trimester in Pregnant Women With APS
Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)
- Trial name
- NCT02303171
- Testing
- Enoxaparin, Warfarin
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Mohamed Sayed Abdelhafez
Antiphospholipid Syndrome, Thrombosis
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
- Conditions
- Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- OBSTINATE (NCT04262492)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Stéphane Zuily
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06723106
- Testing
- RAY121
- Where
- 62 sites in Australia, Austria and 17 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
SARS-COV-2
Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant
SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke…
- Trial name
- LA-COVID (NCT05075928)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Antiphospholipid Syndrome (APS)
Effect of Telitacicept on Antibody Titers in Primary APS Patients
The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.
- Trial name
- NCT06315530
- Testing
- Telitacicept+SOC, SOC
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can…
- Trial name
- PROMISSE (NCT00198068)
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Antiphospholipid Syndrome
A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)
The main purpose of this study is to evaluate the efficacy of crovalimab compared with placebo as an add-on therapy to vitamin K antagonist (VKA) in participants with APS.
- Trial name
- NCT07172022
- Testing
- Crovalimab, VKA
- Sponsor
- Hoffmann-La Roche
Antiphospholipid Syndrome, Arterial Thrombosis
Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12…
- Trial name
- NCT05646394
- Testing
- Dual antiplatelet therapy, Combined antithrombotic therapy, Vitamin K antagonist standard intensity
- Where
- 3 sites in Argentina, Canada
- Volunteers
- 150 people
- Sponsor
- McMaster University
Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
This exploratory, single-arm, open-label study will evaluate the safety and preliminary efficacy of YTS109 cell therapy in pediatric patients with relapsed/refractory autoimmune diseases, including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis, Idiopathic Inflammatory Myopathies (IIMs), ANCA Associated Vasculitis (AAV)
- Trial name
- NCT07439029
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Children's Hospital of Fudan University
Antiphospholipid Syndrome (APS)
Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)
This is a phase II, single-centre, open-label pilot study evaluating the safety and tolerability of anifrolumab in adult patients with primary antiphospholipid syndrome (APS).
- Trial name
- AnifAPS (NCT07584083)
- Testing
- Anifrolumab
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- National and Kapodistrian University of Athens
Recurrent Pregnancy Losses, Positive Anti Phospholipid Syndrome
Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome
Preconceptional use of low molecular weight heparin (enoxaparin) and aspirin in patient with recurrent miscarriages with positive anti phospholipid antibodies increase the implantation rate and the duration of pregnancy with low…
- Trial name
- NCT01661439
- Testing
- low molecular weight heparin (enoxeparine)
- Where
- Egypt
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Woman's Health University Hospital, Egypt
High Risk Pregnancy, Pregnancy Complications
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and…
- Conditions
- High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
- Trial name
- NCT03152058
- Testing
- Certolizumab Pegol
- Where
- 3 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- David Ware Branch
Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs)
OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
This registry will make it possible to collect large-scale data on SAPL patients, particularly those treated with DOACs, in order to better assess the frequency of thrombotic and hemorrhagic events in this population of…
- Conditions
- Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs), Thrombotic and Bleeding Events, Safety
- Trial name
- OBSTINATE 2 (NCT06929182)
- Testing
- "non-high risk" thrombotic APS patients treated with DOAC
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Central Hospital, Nancy, France
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.